SUVENPHAR2021-07-012021-09-30in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2021-07-012021-09-30in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2021-07-012021-09-30in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2021-07-012021-09-30in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2021-07-012021-09-30in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2021-07-012021-09-30in-bse-fin:FourOperatingExpenses03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2021-04-01 2022-03-31 2021-10-29 INR Lakhs Half yearly true Cash Flow Indirect Single segment Contract Development and ManufacturingnOperations (CDMO) 2021-07-01 2021-09-30 Unaudited Consolidated 3009883000.00 50411000.00 3060294000.00 1188590000.00 0.00 -262834000.00 231943000.00 11751000.00 91770000.00 634434000.00 1895654000.00 1164640000.00 0.00 1164640000.00 351622000.00 17803000.00 369425000.00 0.00 795215000.00 0.00 0.00 0.00 174633000.00 969848000.00 -2093000.00 967755000.00 0.00 0.00 254565000.00 1 3.81 3.81 0.00 0.00 3.81 3.81 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th November, 2021. The above results have been subjected to limited review by the statutory auditors of the company 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc.,USA and associate Rising Pharma Holdings, Inc., USA 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary, Suven Pharma, Inc., USA. Apart from the above the shortage or non- availability of vessels leading to delay in shipments, increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profiability. 6) The other Income (Standalone figures) includes an amount of Rs.3329.39 Lakhs pertaining to the Dividends received form our Subsiadary.And also the Current tax (Standalone figures) includes an amount of Rs.491.72 Lakhs tax paid on Such Dividend by our subsidiary. 7) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Single segment 2021-04-01 2021-09-30 Unaudited Consolidated 5647896000.00 108240000.00 5756136000.00 2106986000.00 0.00 -413725000.00 443532000.00 33006000.00 181703000.00 1147259000.00 3498761000.00 2257375000.00 0.00 2257375000.00 623257000.00 24562000.00 647819000.00 0.00 1609556000.00 0.00 0.00 0.00 411123000.00 2020679000.00 -4186000.00 2016493000.00 0.00 0.00 254565000.00 1 7.94 7.94 0.00 0.00 7.94 7.94 Manufacturing Expense 437388000.00 Other Expense 160352000.00 R & D expense 36694000.00 Manufacturing Expense 825871000.00 Other Expense 261170000.00 R & D expense 60218000.00 33006000.00 -635423000.00 -606003000.00 0.00 0.00 0.00 -3094000.00 -30849000.00 0.00 151994000.00 0.00 46245000.00 0.00 177548000.00 0.00 -175000.00 0.00 64121000.00 0.00 -5183000.00 0.00 1660000.00 0.00 -43834000.00 -411123000.00 0.00 -7000.00 0.00 0.00 -442191000.00 1815184000.00 0.00 0.00 0.00 588068000.00 0.00 1227116000.00 0.00 46873000.00 0.00 0.00 0.00 0.00 0.00 0.00 6000.00 424515000.00 -244937000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5099000.00 0.00 0.00 0.00 -2658000.00 0.00 -713878000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -116791000.00 12591000.00 0.00 -3383000.00 254565000.00 33006000.00 0.00 1890000.00 -411680000.00 101558000.00 71823000.00 173381000.00 -3000.00 173378000.00